Immunoproteasome inhibitor-doxorubicin conjugates target multiple myeloma cells and release doxorubicin upon low-dose photon irradiation

Autor: Santina Maiorana, Elmer Maurits, Bogdan I. Florea, Patrick M Dekker, Herman S. Overkleeft, Dennis P A Wander, Sander I. van Kasteren, Sabina Y van der Zanden, Michel J. van de Graaff, Jacques Neefjes

Publikováno v: Journal of the American Chemical Society, 142(16), 7250-7253. AMER CHEMICAL SOC
Journal of the American Chemical Society
Journal of the American Chemical Society, 142(16), 7250-7253

Proteasome inhibitors are established therapeutic agents for the treatment of hematological cancers, as are anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug classes into a single molecule. Doxo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c650855c83969ab31b88fc36969ee0
https://hdl.handle.net/1887/3181191